By Dr Chun Tang — MBChB (Manchester), MRCGP, MBA · Practising NHS & Private GP · Founder, Little Ox

Fibromyalgia, Mitochondrial Dysfunction and NAD+: What the 2024 Research Shows

Fibromyalgia is one of the most challenging conditions I encounter in general practice. It affects an estimated 2–4% of the UK population, is significantly more common in women, and remains poorly understood — even by clinicians who see it regularly. The combination of widespread chronic pain, profound fatigue, sleep disruption and cognitive symptoms ("fibro fog") creates a burden that standard pain management often addresses only partially.

One of the most interesting developments in fibromyalgia research over the past two years has been a significant focus on mitochondrial dysfunction as a potential driver of the condition's core symptoms. And where mitochondria are involved, NAD+ — and therefore NMN — enters the picture.

I want to be precise about what the evidence shows and what it doesn't, because people with fibromyalgia deserve honesty, not supplements oversold on thin science.

The New Mitochondrial Evidence in Fibromyalgia

For years, the pathophysiology of fibromyalgia was understood primarily through the lens of central sensitisation — an abnormal amplification of pain signals in the central nervous system. That understanding remains important. But a growing body of research is now pointing to mitochondrial dysfunction as a parallel and possibly primary contributor to fibromyalgia's symptom burden.

In June 2024, researchers from the Weizmann Institute of Science published a landmark electron microscopy study examining the mitochondria of fibromyalgia patients directly, at ultrastructural level. They found that fibromyalgia patients showed a significant reduction in mitochondrial cristae — the inner membrane folds where ATP production (cellular metabolism generation) takes place. In some patients' cells, cristae were completely absent. The severity of mitochondrial structural damage correlated directly with pain severity scores.

The researchers proposed that the loss of cristae represents mitochondria entering a state of functional dormancy — essentially shutting down non-essential energy production under conditions of chronic cellular stress. This mitochondrial hibernation, they suggested, could explain the profound fatigue and exercise intolerance that characterises fibromyalgia, alongside central sensitisation mechanisms.

A separate 2024 study published in Scientific Reports examined mitochondrial function in blood cells from 50 fibromyalgia patients versus healthy controls. It found a significantly lower bioenergetic health index (BHI) in fibromyalgia patients — a composite measure of mitochondrial efficiency — with the most severe functional impairment in the most severely affected patients. Critically, the researchers proposed BHI as a potential objective biomarker for fibromyalgia severity, which matters because the condition currently has no validated biological test.

A third 2024 study looked at skeletal muscle in fibromyalgia models and found impaired electron transport chain activity — specifically reduced function of complexes I, III and IV, which are the mitochondrial enzymes that use NADH (the reduced form of NAD+) to generate ATP. CoQ10 deficiency, an established finding in fibromyalgia patients' blood cells from earlier research, sits in the same mitochondrial electron transport pathway.

The NAD+ Connection

NAD+ is the central molecule in mitochondrial energy production. The electron transport chain — the process by which mitochondria generate ATP — requires NAD+ as its primary electron carrier. Complex I, the first enzyme in the chain and the one most consistently implicated in fibromyalgia mitochondrial research, uses NADH (NAD+ carrying electrons) as its direct substrate.

When NAD+ is depleted or insufficiently available, Complex I function is impaired. The mitochondria produce less ATP. Cells that depend on consistent energy supply — including muscle cells and neurons — begin to malfunction. This produces exactly the symptom pattern fibromyalgia patients describe: pain that seems out of proportion to visible pathology, fatigue that rest doesn't relieve, and cognitive difficulties in the absence of neurological disease.

The additional finding of reduced PGC-1α expression in fibromyalgia models is also significant. PGC-1α is the master regulator of mitochondrial biogenesis — the process by which cells create new mitochondria to replace damaged ones. NAD+ activates SIRT1, which in turn activates PGC-1α. Lower NAD+ → reduced SIRT1 activity → reduced mitochondrial biogenesis → fewer functional mitochondria. This is a compounding cycle, and it runs in exactly the direction that fibromyalgia research is documenting.

What NMN Does — and What We Don't Yet Know

NMN raises cellular NAD+ levels. This has been confirmed in multiple human clinical trials at doses of 250–500mg daily. Higher NAD+ supports Complex I function, reduces oxidative stress, activates SIRT1 and PGC-1α, and may support mitochondrial biogenesis.

There are no completed clinical trials testing NMN specifically in fibromyalgia patients. I want to be clear about that. The evidence base for NMN in fibromyalgia is mechanistic — the biological reasoning is sound, but the direct clinical proof does not yet exist.

What we do have is:

• Strong 2024 evidence that mitochondrial dysfunction — specifically reduced electron transport chain activity and NAD+ pathway impairment — is central to fibromyalgia pathology
• Confirmed human trial evidence that NMN raises NAD+ levels and supports mitochondrial function
• A 2024 human trial showing NMN improved physical performance scores and reduced fatigue markers in middle-aged adults
• Preliminary reports that NAD+ precursor supplementation produces moderate improvements in energy and quality of life in fibromyalgia and chronic fatigue conditions
• Good safety data: NMN at 500mg daily is well-tolerated with no significant adverse effects in all completed human trials

The Fatigue Symptom — The Most Relevant Target

Fibromyalgia pain involves multiple mechanisms, and NMN is not an analgesic. It does not directly address central sensitisation, which is the primary driver of the pain amplification that characterises the condition. Standard pain management, physiotherapy, sleep hygiene and psychological approaches remain the mainstay of fibromyalgia treatment.

Where NMN's evidence base is most directly applicable is the fatigue and energy depletion that fibromyalgia patients consistently describe as one of their most debilitating symptoms. The fatigue of fibromyalgia — characterised by the sense that the body's energy supply is fundamentally inadequate, that recovery from activity is disproportionately slow, and that cognitive stamina depletes rapidly — maps closely onto the mitochondrial energy deficit that 2024 research is documenting. This is the target for cellular metabolism support.

Sleep — The Other Critical Dimension

Fibromyalgia and sleep have a well-documented bidirectional relationship. Poor sleep worsens pain and fatigue in fibromyalgia; fibromyalgia disrupts sleep architecture. Unrefreshing sleep patterns — waking unrefreshed despite sufficient hours — is reported by the majority of fibromyalgia patients and is thought to contribute to central sensitisation and symptom perpetuation.

A 2024 randomised controlled trial found that NMN supplementation significantly improved recovery and overnight routine in older adults, including measures of daytime dysfunction and global recovery and overnight routine. NAD+ regulates circadian clock genes — the molecular timekeeping system that governs sleep-wake cycles — and restoring NAD+ may support more consistent circadian regulation. For fibromyalgia patients whose sleep is chronically disrupted, this is a relevant consideration alongside NMN's mitochondrial energy support.

For this reason, I'd suggest pairing NMN with Magnesium Glycinate in the evening. Magnesium glycinate — the most bioavailable form — supports GABA pathways involved in sleep regulation, and magnesium deficiency is prevalent in fibromyalgia patients. The morning NMN / evening magnesium combination addresses cellular metabolism and recovery and overnight routine simultaneously — the two dimensions most directly supported by current evidence.

What Else the Evidence Supports in Fibromyalgia

The 2024 research on fibromyalgia mitochondrial dysfunction also tested Boswellia serrata — a plant extract with anti-inflammatory and antioxidant properties — and found it significantly restored mitochondrial function in fibromyalgia models, including recovering PGC-1α expression and electron transport chain activity. This is interesting because the mechanism runs through the same pathways that NAD+ and NMN address, suggesting that antioxidant/mitochondrial-related research approaches have genuine relevance in this condition regardless of specific compound.

CoQ10 supplementation also has a small evidence base in fibromyalgia, based on the established CoQ10 deficiency finding. It addresses the adjacent electron transport chain step (Complex II/III) to NAD+ (Complex I).

Aerobic exercise — counterintuitive given fibromyalgia's post-exertional malaise — remains one of the best-evidenced interventions in fibromyalgia at appropriate intensity levels, partly because it stimulates mitochondrial biogenesis through PGC-1α activation. NMN's NAD+/SIRT1/PGC-1α pathway activation is a cellular complement to exercise's physiological effects.

Shop NMN Plus — from £9.99 → Shop Magnesium Glycinate — £9.99 →

---

This article is for informational purposes only and does not constitute medical advice. NMN is a food supplement, not a medicine, and is not intended to diagnose, treat, cure or prevent fibromyalgia or any other condition. If you have fibromyalgia, please work with your GP or specialist on an appropriate treatment plan. Do not alter or stop any prescribed medication without medical advice.